Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial.

about

Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial.

Item

http://www.wikidata.org/entity/Q55376651

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Efficacy of two different dosa ...... er, randomized clinical trial.

@en

Efficacy of two different dosa ...... er, randomized clinical trial.

@nl

type

Item

label

Efficacy of two different dosa ...... er, randomized clinical trial.

@en

Efficacy of two different dosa ...... er, randomized clinical trial.

@nl

prefLabel

Efficacy of two different dosa ...... er, randomized clinical trial.

@en

Efficacy of two different dosa ...... er, randomized clinical trial.

@nl

P1476

Efficacy of two different dosa ...... er, randomized clinical trial.

@en

P2093

Huo-Ye Gan

http://www.w3.org/2001/XMLSchema#string

Kai-Hua Su

http://www.w3.org/2001/XMLSchema#string

Li-Ya Yao

http://www.w3.org/2001/XMLSchema#string

Lin-Li Zhao

http://www.w3.org/2001/XMLSchema#string

Rong-Jiao Yang

http://www.w3.org/2001/XMLSchema#string

Tie-Li Peng

http://www.w3.org/2001/XMLSchema#string

You-Ming Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Kyoto global consensus report on Helicobacter pylori gastritis

The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.

Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial.

Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection

Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.

Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy.

Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance.

High efficacy of gemifloxacin-containing therapy in Helicobacter Pylori eradication: A pilot empirical second-line rescue therapy.

Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial.

Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy.

P304

9045

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-018-27482-2

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29899426

http://www.w3.org/2001/XMLSchema#string

P921

Helicobacter pylori

P932

5998071

http://www.w3.org/2001/XMLSchema#string